Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death

Apoptosis

Volumn 15, Issue 10, 2010, Pages 1223-1233

  Skommer, Joanna ^a   Brittain, Tom ^a   Raychaudhuri, Subhadip ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b University of California   (United States)

Author keywords

Apoptosis; Bcl 2; Cancer; Stochastic variability; Systems biology

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL 2; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL KILLING; CONCENTRATION RESPONSE; ENZYME ACTIVITY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MONTE CARLO METHOD; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOCHASTIC MODEL; TIME;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BENZOPYRANS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE, TUMOR; CYTOCHROMES C; FLOW CYTOMETRY; GENES, BCL-2; HUMANS; JURKAT CELLS; MITOCHONDRIA; NITRILES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 78650048538     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-010-0515-7     Document Type: Article

References (40)

1. Letai A, Bassik MC, Walensky LD et al (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183-192
2. Kim H, Tu HC, Ren D et al (2009) Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 36:487-499
3. Chonghaile TN, Letai A (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27(Suppl 1):S149-S157
4. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ (2004) Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6:241-249
5. Certo M, Del Gaizo Moore V, Nishino M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365
6. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126-1132
7. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324-1337
8. Skommer J, Wlodkowic D, Deptala A (2007) Larger than life: mitochondria and the Bcl-2 family. Leuk Res 31:277-286
9. Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK (2008) Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol 6:2831-2852
10. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK (2009) Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459:428-432
11. Raychaudhuri S, Willgohs E, Nguyen TN, Khan EM, Goldkorn T (2008) Monte Carlo simulation of cell death signaling predicts large cell-to-cell stochastic fluctuations through the type 2 pathway of apoptosis. Biophys J 95:3559-3562
12. Raychaudhuri S, Tsourkas PK, Willgohs E (2009) Computational modeling of receptor-ligand binding and cellular signaling processes. In: Jue T (ed) Handbook of modern biophysics, fundamentals, vol 1, chap 3. Humana Press, New York
13. Raychaudhuri S, Skommer J, Henty K, Birch N, Brittain T (2010) Neuroglobin protects nerve cells from apoptosis by inhibiting the intrinsic pathway of cell death. Apoptosis 15:401-411
14. Skommer J, Wlodkowic D, Mättö M, Eray M, Pelkonen J (2006) HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res 30:322-331
15. Wlodkowic D, Skommer J, McGuinness D et al (2010) Chipbased dynamic real-time quantification of drug-induced cytotoxicity in human tumor cells. Anal Chem 81:6952-6959
16. Qian S, Wang W, Yang L, Huang HW (2008) Structure of transmembrane pore induced by Bax-derived peptide: evidence for lipidic pores. Proc Natl Acad Sci USA 105:17379-17383
17. McAdams HH, Arkin A (1999) It's a noisy business! Genetic regulation at the nanomolar scale. Trends Genet 15:65-69
18. Elowitz MB, Levine AJ, Siggia ED, Swain PS (2002) Stochastic gene expression in a single cell. Science 297:1183-1186
19. Fedoroff N, Fontana W (2002) Genetic networks: small numbers of big molecules. Science 297:119-1131
20. Sigal A, Milo R, Cohen A, Geva-Zatorsky N, Klein Y, Liron Y, Rosenfeld N, Danon T, Perzov N, Alon U (2006) Variability and memory of protein levels in human cells. Nature 444:643-646
21. Wang JL, Liu D, Zhang ZJ et al (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97:7124-7129
22. Fussenegger M, Bailey JE, Verner J (2000) A mathematical model of caspase function in apoptosis. Nat Biotechnol 18:768-774
23. Hua F, Cornejo MG, Cardone MH, Stokes CL, Lauffenburger DA (2005) Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions. J Immunol 175:985-995
24. Eissing T, Conzelmann H, Gilles ED et al (2004) Bistability analyses of a caspase activation model for receptor-induced apoptosis. J Biol Chem 79:36892-36897
25. Bagci EZ, Vodovotz Y, Billiar TR et al (2006) Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 90:1546-1559
26. Manero F, Gautier F, Gallenne T et al (2006) The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757-2764
27. Goldstein JC, Muñoz-Pinedo C, Ricci JE et al (2005) Cytochrome c is released in a single step during apoptosis. Cell Death Differ 12:453-462
28. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2:156-162
29. Düssmann H, Rehm M, Concannon CG et al (2010) Single-cell quantification of Bax activation and mathematical modeling suggest pore formation on minimal mitochondrial Bax accumulation. Cell Death Differ 17:278-290
30. Düssmann H, Rehm M, Kögel D, Prehn JH (2003) Outer mitochondrial membrane permeabilization during apoptosis triggers caspase-independent mitochondrial and caspase-dependent plasma membrane potential depolarization: a single-cell analysis. J Cell Sci 116:525-536
31. Legewie S, Blüthgen N, Herzel H (2006) Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. PLoS Comput Biol 2:e120
32. Geva-Zatorsky N, Rosenfeld N, Itzkovitz S et al (2006) Oscillations and variability in the p53 system. Mol Syst Biol 2: 2006.0033
33. Enderling H, Anderson AR, Chaplain MA, Beheshti A, Hlatky L, Hahnfeldt P (2009) Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res 69:8814-8821
34. Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267-1270
35. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593-598
36. Niepel M, Spencer SL, Sorger PK (2009) Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol 13:556-561
37. MacDiarmid JA, Mugridge NB, Weiss JC et al (2007) Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11:431-445
38. Rieder CL, Medema RH (2009) No way out for tumor cells. Cancer Cell 16:274-275
39. Vangestel C, Van de Wiele C, Mees G, Peeters M (2009) Forcing cancer cells to commit suicide. Cancer Biother Radiopharm 24:395-407
40. Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894-4903